VivoSeq
Oncology

Liposarcoma

28

Pipeline Programs↗

6

Active Trials↗

22

Companies Involved↗

Liposarcoma is an emerging landscape with 28 programs across 22 companies. The most active players are Roche, Edgewood Oncology Inc., GSK. 4 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

52/100

Pipeline Velocity

0/100

Mech. Concentration

25/100

Completion Rate

86/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

1 program

Phase 1E

Edgewood Oncology Inc.

1 program

Phase 1GSK logo

GSK

2 programs

Phase 2Pfizer logo

Pfizer

2 programs

Phase 2Sanofi logo

Sanofi

2 programs

Phase 2Ascentage Pharma Group Inc. logo

Ascentage Pharma Group Inc.

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

93%

Small molecule

26 of 28 classified programs — the dominant modality here.

7%ALL OTHERSMonoclonal antibody14%Cell therapy14%

Small molecule leads; the ring shows all 28 classified programs, each share of the total. Modality classified for 100% of 28 pipeline programs.

Analysis

Trial Status

20

clinical trials

Completed12 · 60%
Active, not recruiting3 · 15%
Recruiting3 · 15%
Terminated2 · 10%

Clinical Trials

Trial Activity

20 trials

A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma
Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT06843967·54 enrolled
APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors
Recruiting·Ascentage Pharma Group Inc. logoAscentage Pharma Group Inc.·Phase 1/2·NCT04785196·95 enrolled
Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma
Recruiting·AAustralia and New Zealand Sarcoma Association·N/A·NCT07377747·100 enrolled
Palbociclib and INCMGA00012 in People With Advanced Liposarcoma
Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT04438824·42 enrolled
Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by Surgery
Active, not recruiting·OOHSU Knight Cancer Institute·Phase 1·NCT03361436·15 enrolled
A Pilot Study of BTX-A51 in Patients With Metastatic and/or Recurrent Liposarcomas Characterized by MDM2 Amplifications, Myxoid Liposarcoma, and CIC-Rearranged Sarcoma
Active, not recruiting·MMichael Wagner, MD·Phase 1·NCT06414434·24 enrolled
A Study of RO5045337 in Patients With Liposarcomas Prior to Debulking Surgery
Completed·Roche logoRoche·Phase 1·NCT01143740·20 enrolled
Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma
Completed·Novartis logoNovartis·Phase 1·NCT02343172·74 enrolled
PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma
Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT01209598·90 enrolled
Troglitazone in Treating Patients With Liposarcoma
Completed·—·Phase 2·NCT00003058·85 enrolled
Rosiglitazone in Treating Patients With Liposarcoma
Completed·—·Phase 2·NCT00004180·32 enrolled
A Trial of Oral 5-azacitidine in Combination With Romidepsin in Advanced Solid Tumors, With an Expansion Cohort in Virally Mediated Cancers and Liposarcoma
Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT01537744·18 enrolled
Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma
Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logoJohnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00579501·29 enrolled
Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma
Completed·GSK logoGSK·Phase 2·NCT02992743·23 enrolled
Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma
Completed·VVector Oncology·Phase 2·NCT01506596·42 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)